| __timestamp | CymaBay Therapeutics, Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 15823000 | 189101000 |
| Thursday, January 1, 2015 | 17026000 | 96351000 |
| Friday, January 1, 2016 | 15941000 | 95967000 |
| Sunday, January 1, 2017 | 18938000 | 112171000 |
| Monday, January 1, 2018 | 58124000 | 182257000 |
| Tuesday, January 1, 2019 | 83837000 | 336964000 |
| Wednesday, January 1, 2020 | 35882000 | 547851000 |
| Friday, January 1, 2021 | 64542000 | 693716000 |
| Saturday, January 1, 2022 | 67995000 | 891813000 |
| Sunday, January 1, 2023 | 80118000 | 1044071000 |
| Monday, January 1, 2024 | 910408000 |
In pursuit of knowledge
In the dynamic world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Exelixis, Inc. and CymaBay Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Exelixis has consistently outpaced CymaBay, with its R&D expenses growing by over 450%, peaking in 2023. This surge underscores Exelixis's aggressive strategy to expand its research capabilities. In contrast, CymaBay's R&D spending, while more modest, has shown a steady increase of approximately 400% over the same period, reflecting a more measured approach. The year 2019 marked a significant leap for both companies, with CymaBay nearly doubling its R&D budget, while Exelixis increased its spending by 85%. These trends highlight the diverse strategies employed by biotech firms in their quest for groundbreaking therapies.
R&D Spending Showdown: AstraZeneca PLC vs CymaBay Therapeutics, Inc.
Research and Development Investment: Gilead Sciences, Inc. vs CymaBay Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and Exelixis, Inc.
Research and Development Expenses Breakdown: Zoetis Inc. vs Exelixis, Inc.
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ionis Pharmaceuticals, Inc.
Research and Development Investment: Exelixis, Inc. vs Alkermes plc
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Exelixis, Inc. and ACADIA Pharmaceuticals Inc.
R&D Spending Showdown: Alpine Immune Sciences, Inc. vs CymaBay Therapeutics, Inc.
R&D Spending Showdown: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
R&D Insights: How CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd. Allocate Funds
Analyzing R&D Budgets: CymaBay Therapeutics, Inc. vs MiMedx Group, Inc.